Sulforaphane / Glucoraphanin (Truebroc®)

Brassica oleracea var. italica
Evidence Level
Strong
3 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

Sulforaphane is an isothiocyanate compound produced when glucoraphanin — found in broccoli seeds and sprouts — contacts the enzyme myrosinase during chewing or supplement processing. Truebroc® (Brassica Protection Products) is a standardized glucoraphanin extract from broccoli seeds that reliably delivers sulforaphane precursor. One of the most potent natural activators of the Nrf2 antioxidant pathway, sulforaphane has clinical evidence for cancer chemoprevention, detoxification, autism spectrum disorder, and cardiovascular health.

Studied Dose 30–60 mg/day glucoraphanin (equivalent to ~10–20 mg sulforaphane); 100g fresh broccoli sprouts provides ~30–50 mg glucoraphanin
Active Compound Glucoraphanin (sulforaphane precursor) — Truebroc® by Brassica Protection Products; SGS™ (Sulforaphane Glucosinolate) standardized ≥13%

Nrf2 pathway activation and antioxidant defense

Sulforaphane is the most potent known natural activator of Nrf2 — the master transcription factor governing expression of over 200 cytoprotective genes including glutathione S-transferases, heme oxygenase-1, NQO1, and superoxide dismutase. Effects last 24–72 hours per dose due to sustained Nrf2 activation.

Cancer chemoprevention

Sulforaphane inhibits phase I carcinogen-activating enzymes while inducing phase II detoxification enzymes that neutralize carcinogens before DNA damage occurs. Epidemiological and clinical trial data supports inverse association between cruciferous vegetable consumption and risk of lung, breast, prostate, and colorectal cancers.

Autism spectrum disorder symptoms

A landmark Johns Hopkins double-blind RCT showed sulforaphane (50–150 μmol/day) significantly improved social interaction, aberrant behavior, and verbal communication in young men with moderate-to-severe ASD over 18 weeks — the largest effect size of any compound tested in ASD to date.

Cardiovascular and metabolic health

Sulforaphane reduces oxidized LDL, improves endothelial function via Nrf2-driven HO-1 expression, and significantly reduces fasting blood glucose and HbA1c in type 2 diabetic patients — effects demonstrated in a clinical trial published in Science Translational Medicine.

Detoxification and pollution protection

Sulforaphane accelerates urinary excretion of benzene, acrolein, and other airborne carcinogens by upregulating glutathione conjugation and mercapturic acid pathway enzymes. Clinical trial in China showed 61–69% increased excretion of benzene and acrolein in polluted urban environment.

1

Nrf2-Keap1 pathway activation

Sulforaphane modifies cysteine residues on Keap1 (the Nrf2 repressor protein), preventing Keap1-mediated Nrf2 ubiquitination and proteasomal degradation. Free Nrf2 translocates to the nucleus and binds antioxidant response elements (AREs), inducing transcription of over 200 cytoprotective genes simultaneously.

2

Histone deacetylase (HDAC) inhibition

Sulforaphane inhibits class I and II histone deacetylases, maintaining chromatin in an open, transcription-accessible state at tumor suppressor gene loci. This epigenetic mechanism contributes to its cancer preventive effects independently of Nrf2 activation.

3

Phase II detoxification enzyme induction

Sulforaphane induces glutathione S-transferases (GSTs), NQO1 (NAD(P)H quinone oxidoreductase), and epoxide hydrolases that convert reactive carcinogen metabolites to water-soluble mercapturic acid conjugates for urinary excretion — providing systemic chemoprotection.

1
Sulforaphane and Autism Spectrum Disorder — Johns Hopkins RCT
PubMed

Randomized, double-blind, placebo-controlled trial of sulforaphane (50–150 μmol/day from broccoli sprout extract) in 29 young men with moderate-to-severe ASD for 18 weeks.

29 young men with ASD aged 13–27. 18-week intervention.

Sulforaphane significantly improved social responsiveness (SRS: -34%), aberrant behavior (ABC: -17%), and social communication vs. placebo. Effects reversed upon discontinuation. No serious adverse events. Largest effect size of any compound in ASD clinical trials.

2
Sulforaphane and Blood Glucose in Type 2 Diabetes — Science Translational Medicine
PubMed

Clinical trial examining sulforaphane (concentrated broccoli sprout extract delivering ~150 μmol sulforaphane/day) in 97 patients with type 2 diabetes for 12 weeks.

97 T2DM patients. 12-week intervention.

Sulforaphane significantly reduced fasting blood glucose (significant in obese dysregulated subgroup) and HbA1c vs. placebo. Mechanism confirmed as NRF2-mediated suppression of glucose production enzymes in liver. Published in Science Translational Medicine.

3
Sulforaphane and Air Pollutant Detoxification — China RCT
PubMed

Randomized, placebo-controlled trial of broccoli sprout beverage (delivering ~26–40 μmol sulforaphane/day) in 291 healthy adults in polluted Jiangsu province, China for 12 weeks.

291 healthy adults in heavily polluted region. 12-week intervention.

Broccoli sprout drink significantly increased urinary excretion of benzene (61%), acrolein (23%), and crotonaldehyde (23%) vs. placebo — demonstrating real-world protection against air pollution carcinogens.

Common Potential side effects

Generally well tolerated at clinical doses
GI discomfort and flatulence possible — especially with high doses of broccoli sprout preparations
Sulfurous body odor/breath at high doses (same mechanism as garlic odor)
Hypothyroid individuals should use caution — glucosinolates may mildly affect thyroid at very high doses

Important Drug interactions

Anticoagulants (warfarin) — sulforaphane induces CYP1A2 and CYP2B6; may alter warfarin metabolism; monitor INR
Chemotherapy — sulforaphane has complex interactions; may sensitize some tumors to chemotherapy while protecting normal cells; discuss with oncologist
CYP substrates — Nrf2 induction affects multiple CYP enzymes; potential interactions with medications metabolized by CYP1A2, 2B6